CN109160951A
(zh)
|
2010-11-30 |
2019-01-08 |
中外制药株式会社 |
细胞毒诱导治疗剂
|
BR112014004168A2
(pt)
|
2011-08-23 |
2017-12-12 |
Roche Glycart Ag |
anticorpo biespecífico, composição farmacêutica, uso do anticorpo biespecífico, célula hospedeira procariótica ou eucariótica, método de produção de anticorpo e invenção
|
US10851178B2
(en)
|
2011-10-10 |
2020-12-01 |
Xencor, Inc. |
Heterodimeric human IgG1 polypeptides with isoelectric point modifications
|
TWI679212B
(zh)
|
2011-11-15 |
2019-12-11 |
美商安進股份有限公司 |
針對bcma之e3以及cd3的結合分子
|
JOP20200236A1
(ar)
|
2012-09-21 |
2017-06-16 |
Regeneron Pharma |
الأجسام المضادة لمضاد cd3 وجزيئات ربط الأنتيجين ثنائية التحديد التي تربط cd3 وcd20 واستخداماتها
|
CN104704004B
(zh)
|
2012-10-08 |
2019-12-31 |
罗切格利卡特公司 |
包含两个Fab片段的无Fc的抗体及使用方法
|
SI2943511T1
(sl)
|
2013-01-14 |
2020-01-31 |
Xencor, Inc. |
Novi heterodimerni proteini
|
US10487155B2
(en)
|
2013-01-14 |
2019-11-26 |
Xencor, Inc. |
Heterodimeric proteins
|
US10968276B2
(en)
|
2013-03-12 |
2021-04-06 |
Xencor, Inc. |
Optimized anti-CD3 variable regions
|
US10131710B2
(en)
|
2013-01-14 |
2018-11-20 |
Xencor, Inc. |
Optimized antibody variable regions
|
US11053316B2
(en)
|
2013-01-14 |
2021-07-06 |
Xencor, Inc. |
Optimized antibody variable regions
|
US9605084B2
(en)
|
2013-03-15 |
2017-03-28 |
Xencor, Inc. |
Heterodimeric proteins
|
TWI635098B
(zh)
|
2013-02-01 |
2018-09-11 |
再生元醫藥公司 |
含嵌合恆定區之抗體
|
BR112015017800A2
(pt)
|
2013-02-26 |
2017-11-21 |
Roche Glycart Ag |
moléculas de ligação ao antígeno biespecífica ativadora de célula t, polinucleotídeo, polipeptídeo, vetor, célula hospedeira, método de produção da molécula de ligação ao antígeno biespecífica ativadora de célula t, composição farmacêutica e uso da molécula de ligação ao antígeno biespecífica ativadora de célula t
|
PL2961771T3
(pl)
|
2013-02-26 |
2020-06-01 |
Roche Glycart Ag |
Dwuswoiste cząsteczki wiążące antygen swoisty dla CD3 i CEA aktywujące limfocyty T
|
US10858417B2
(en)
|
2013-03-15 |
2020-12-08 |
Xencor, Inc. |
Heterodimeric proteins
|
DK2970486T3
(en)
|
2013-03-15 |
2018-08-06 |
Xencor Inc |
MODULATION OF T-CELLS WITH BISPECIFIC ANTIBODIES AND FC-FUSIONS
|
AR095374A1
(es)
|
2013-03-15 |
2015-10-14 |
Amgen Res (Munich) Gmbh |
Moléculas de unión para bcma y cd3
|
AR095196A1
(es)
|
2013-03-15 |
2015-09-30 |
Regeneron Pharma |
Medio de cultivo celular libre de suero
|
US10519242B2
(en)
|
2013-03-15 |
2019-12-31 |
Xencor, Inc. |
Targeting regulatory T cells with heterodimeric proteins
|
KR101815265B1
(ko)
*
|
2013-06-20 |
2018-01-04 |
한올바이오파마주식회사 |
FcRn 특이적 인간 항체 및 이를 포함하는 자가면역 질환 치료용 조성물
|
ES2912932T3
(es)
|
2013-07-25 |
2022-05-30 |
Cytomx Therapeutics Inc |
Anticuerpos multiespecíficos, anticuerpos activables multiespecíficos y procedimientos de uso de los mismos
|
EP3083689B1
(en)
|
2013-12-17 |
2020-05-27 |
Genentech, Inc. |
Anti-cd3 antibodies and methods of use
|
TWI681969B
(zh)
|
2014-01-23 |
2020-01-11 |
美商再生元醫藥公司 |
針對pd-1的人類抗體
|
TWI680138B
(zh)
|
2014-01-23 |
2019-12-21 |
美商再生元醫藥公司 |
抗pd-l1之人類抗體
|
WO2015121383A1
(en)
|
2014-02-12 |
2015-08-20 |
Michael Uhlin |
Bispecific antibodies for use in stem cell transplantation
|
TWI701042B
(zh)
|
2014-03-19 |
2020-08-11 |
美商再生元醫藥公司 |
用於腫瘤治療之方法及抗體組成物
|
SG10202008629XA
(en)
|
2014-03-28 |
2020-10-29 |
Xencor Inc |
Bispecific antibodies that bind to cd38 and cd3
|
IL278350B
(en)
|
2014-04-03 |
2022-06-01 |
Igm Biosciences Inc |
J-chain qualified
|
SG11201607434WA
(en)
|
2014-04-07 |
2016-10-28 |
Chugai Pharmaceutical Co Ltd |
Immunoactivating antigen-binding molecule
|
US11505605B2
(en)
|
2014-05-13 |
2022-11-22 |
Chugai Seiyaku Kabushiki Kaisha |
T cell-redirected antigen-binding molecule for cells having immunosuppression function
|
BR112017001579A2
(pt)
|
2014-07-25 |
2017-11-21 |
Cytomx Therapeutics Inc |
anticorpos anti-cd3, anticorpos anti-cd3 ativáveis, anticorpos anti-cd3 multiespecíficos, anticorpos anti-cd3 ativáveis multiespecíficos e métodos de uso dos mesmos
|
MA50584A
(fr)
|
2014-08-04 |
2020-09-16 |
Hoffmann La Roche |
Molécules bispécifiques de liaison à l'antigène activant des lymphocytes t
|
WO2016019969A1
(en)
|
2014-08-08 |
2016-02-11 |
Ludwig-Maximilians-Universität München |
Subcutaneously administered bispecific antibodies for use in the treatment of cancer
|
AR101846A1
(es)
|
2014-09-12 |
2017-01-18 |
Genentech Inc |
Anticuerpos anti-cll-1 e inmunoconjugados
|
JP6932639B2
(ja)
|
2014-09-29 |
2021-09-08 |
デューク ユニバーシティ |
Hiv‐1エンベロープ標的化アームを備える二重特異性分子
|
WO2016077720A1
(en)
*
|
2014-11-14 |
2016-05-19 |
Protein One, Llc |
Binding agents and uses thereof
|
KR102614189B1
(ko)
*
|
2014-11-17 |
2023-12-18 |
리제너론 파아마슈티컬스, 인크. |
Cd3xcd20 이특이적 항체를 이용한 종양의 치료 방법
|
PL3221355T3
(pl)
|
2014-11-20 |
2021-03-08 |
F. Hoffmann-La Roche Ag |
Terapia skojarzona składająca się z dwuswoistych aktywujących limfocyty T cząsteczek wiążących antygen CD3 i receptor folianowy 1 (FolR1) oraz antagonistów wiązania osi PD-1
|
SG11201703800PA
(en)
*
|
2014-11-24 |
2017-06-29 |
Regeneron Pharma |
Non-human animals expressing humanized cd3 complex
|
AU2015353416C1
(en)
|
2014-11-26 |
2022-01-27 |
Xencor, Inc. |
Heterodimeric antibodies that bind CD3 and CD38
|
US10259887B2
(en)
|
2014-11-26 |
2019-04-16 |
Xencor, Inc. |
Heterodimeric antibodies that bind CD3 and tumor antigens
|
NZ732144A
(en)
|
2014-11-26 |
2020-04-24 |
Xencor Inc |
Heterodimeric antibodies that bind cd3 and tumor antigens
|
LT3227336T
(lt)
|
2014-12-05 |
2019-09-25 |
F. Hoffmann-La Roche Ag |
Anti-cd79b antikūnai ir jų naudojimo būdai
|
WO2016089610A1
(en)
|
2014-12-06 |
2016-06-09 |
H. Lee Moffitt Cancer Center And Research Institute, Inc. |
Bispecific antibody for cancer immunotherapy
|
ES2717308T3
(es)
|
2014-12-06 |
2019-06-20 |
Gemoab Monoclonals Gmbh |
Células madre pluri- o multi-potentes genéticamente modificadas y sus usos
|
EP3237449A2
(en)
|
2014-12-22 |
2017-11-01 |
Xencor, Inc. |
Trispecific antibodies
|
AU2016205967B2
(en)
*
|
2015-01-08 |
2021-11-11 |
Genmab A/S |
Bispecific antibodies against CD3 and CD20
|
EP3265575B1
(en)
|
2015-03-04 |
2021-04-21 |
IGM Biosciences, Inc. |
Cd20 binding molecules and uses thereof
|
WO2016141387A1
(en)
|
2015-03-05 |
2016-09-09 |
Xencor, Inc. |
Modulation of t cells with bispecific antibodies and fc fusions
|
AU2016232693B2
(en)
|
2015-03-19 |
2021-08-12 |
Duke University |
HIV-1 neutralizing antibodies and uses thereof
|
US10450368B2
(en)
|
2015-03-19 |
2019-10-22 |
Duke University |
HIV-1 neutralizing antibodies and uses thereof (CD4bs antibodies)
|
US10344077B2
(en)
|
2015-03-19 |
2019-07-09 |
Duke University |
HIV-1 neutralizing antibodies and uses thereof (V3 antibodies)
|
US11071783B2
(en)
|
2015-03-19 |
2021-07-27 |
Duke University |
HIV-1 neutralizing antibodies and uses thereof
|
JP6773679B2
(ja)
|
2015-03-30 |
2020-10-21 |
リジェネロン・ファーマシューティカルズ・インコーポレイテッドRegeneron Pharmaceuticals, Inc. |
Fcガンマ受容体に対する結合が低下した重鎖定常領域
|
CA2984134A1
(en)
*
|
2015-05-08 |
2016-11-17 |
Xencor, Inc. |
Heterodimeric antibodies that bind cd3 and tumor antigens
|
EA039429B1
(ru)
*
|
2015-05-13 |
2022-01-26 |
Ридженерон Фармасьютикалз, Инк. |
Способы лечения опухолей с применением биспецифического антитела cd3xcd20
|
CN111234027A
(zh)
|
2015-05-21 |
2020-06-05 |
哈普恩治疗公司 |
三特异性结合蛋白质及使用方法
|
SI3303400T1
(sl)
|
2015-05-28 |
2021-01-29 |
Genentech, Inc. |
Na celicah osnovan test za detektiranje anti-CD3 homodimerov
|
CN104931699A
(zh)
*
|
2015-05-29 |
2015-09-23 |
北京海思特临床检验所有限公司 |
骨髓涂片异常淋巴细胞染色试剂盒及其使用方法
|
AU2016274767B2
(en)
|
2015-06-09 |
2022-05-19 |
Eureka Therapeutics, Inc. |
T cell receptor-like antibody agents specific for EBV latent membrane protein 2A peptide presented by human HLA
|
SI3310814T1
(sl)
|
2015-06-16 |
2023-11-30 |
F. Hoffmann - La Roche Ag |
HUMANIZIRANA IN AFINITETNO DOZORELA PROTITELESA PROTI FcRH5 IN METODE ZA NJIHOVO UPORABO
|
JP6996983B2
(ja)
|
2015-06-16 |
2022-02-21 |
ジェネンテック, インコーポレイテッド |
抗cll-1抗体及び使用方法
|
BR112017024610A2
(pt)
|
2015-06-24 |
2018-07-31 |
F. Hoffmann-La Roche Ag |
anticorpos para receptor antitransferrina com afinidade especificada
|
WO2017005649A1
(en)
*
|
2015-07-09 |
2017-01-12 |
Genmab A/S |
Bispecific and multispecific antibodies and method for isolation of such
|
TWI829617B
(zh)
|
2015-07-31 |
2024-01-21 |
德商安美基研究(慕尼黑)公司 |
Flt3及cd3抗體構築體
|
TWI796283B
(zh)
|
2015-07-31 |
2023-03-21 |
德商安美基研究(慕尼黑)公司 |
Msln及cd3抗體構築體
|
JOP20160154B1
(ar)
*
|
2015-07-31 |
2021-08-17 |
Regeneron Pharma |
أجسام ضادة مضاد لل psma، وجزيئات رابطة لمستضد ثنائي النوعية الذي يربط psma و cd3، واستخداماتها
|
TW202330904A
(zh)
|
2015-08-04 |
2023-08-01 |
美商再生元醫藥公司 |
補充牛磺酸之細胞培養基及用法
|
KR20180053322A
(ko)
*
|
2015-09-21 |
2018-05-21 |
압테보 리서치 앤드 디벨롭먼트 엘엘씨 |
Cd3 결합 폴리펩타이드
|
JP7023231B2
(ja)
*
|
2015-09-23 |
2022-02-21 |
リジェネロン・ファーマシューティカルズ・インコーポレイテッド |
最適化抗cd3二重特異性抗体及びその使用
|
US11639389B2
(en)
|
2015-09-30 |
2023-05-02 |
Igm Biosciences, Inc. |
Binding molecules with modified J-chain
|
JP7065766B2
(ja)
|
2015-09-30 |
2022-05-12 |
アイジーエム バイオサイエンシズ インコーポレイテッド |
改変j鎖を有する結合分子
|
AR106188A1
(es)
|
2015-10-01 |
2017-12-20 |
Hoffmann La Roche |
Anticuerpos anti-cd19 humano humanizados y métodos de utilización
|
AR106189A1
(es)
|
2015-10-02 |
2017-12-20 |
Hoffmann La Roche |
ANTICUERPOS BIESPECÍFICOS CONTRA EL A-b HUMANO Y EL RECEPTOR DE TRANSFERRINA HUMANO Y MÉTODOS DE USO
|
CA2990755A1
(en)
|
2015-10-02 |
2017-04-06 |
F. Hoffman-La Roche Ag |
Bispecific anti-ceaxcd3 t cell activating antigen binding molecules
|
MA43023A
(fr)
|
2015-10-02 |
2018-08-08 |
Hoffmann La Roche |
Anticorps de récepteur de la transferrine humaine/anti-humaine cd20 bispécifique et leurs procédés d'utilisation
|
TWI756187B
(zh)
|
2015-10-09 |
2022-03-01 |
美商再生元醫藥公司 |
抗lag3抗體及其用途
|
RS62437B1
(sr)
|
2015-10-25 |
2021-11-30 |
Sanofi Sa |
Trispecifični i/ili trivalentni vezujući proteini za prevenciju ili lečenje hiv infekcije
|
WO2017086419A1
(ja)
|
2015-11-18 |
2017-05-26 |
中外製薬株式会社 |
液性免疫応答の増強方法
|
US11660340B2
(en)
|
2015-11-18 |
2023-05-30 |
Chugai Seiyaku Kabushiki Kaisha |
Combination therapy using T cell redirection antigen binding molecule against cell having immunosuppressing function
|
CN106810611A
(zh)
*
|
2015-11-30 |
2017-06-09 |
中国科学院深圳先进技术研究院 |
抗cMet和CD3特异性双靶向抗体及其制备方法和应用、含该双靶向抗体表达盒的微环DNA及应用
|
CN106810610A
(zh)
*
|
2015-11-30 |
2017-06-09 |
中国科学院深圳先进技术研究院 |
抗EpCAM和CD3特异性双靶向抗体及其制备方法和应用、含该双靶向抗体表达盒的微环DNA及应用
|
CN108699136B
(zh)
|
2015-12-07 |
2022-03-18 |
Xencor股份有限公司 |
结合cd3和psma的异二聚抗体
|
IL257696B1
(en)
|
2015-12-09 |
2024-07-01 |
Hoffmann La Roche |
Antibody against CD20 type II to reduce the formation of antibodies against drugs
|
IL313952A
(en)
|
2015-12-22 |
2024-08-01 |
Regeneron Pharma |
Combination of anti-PD-1 antibodies and bispecific anti-CD20 / anti-CD3 antibodies for cancer treatment
|
US10596257B2
(en)
|
2016-01-08 |
2020-03-24 |
Hoffmann-La Roche Inc. |
Methods of treating CEA-positive cancers using PD-1 axis binding antagonists and anti-CEA/anti-CD3 bispecific antibodies
|
CN109073635A
(zh)
*
|
2016-01-25 |
2018-12-21 |
豪夫迈·罗氏有限公司 |
用于测定t细胞依赖性双特异性抗体的方法
|
EA039859B1
(ru)
|
2016-02-03 |
2022-03-21 |
Эмджен Рисерч (Мюник) Гмбх |
Биспецифические конструкты антител, связывающие egfrviii и cd3
|
SG11201807936VA
(en)
*
|
2016-03-14 |
2018-10-30 |
Chugai Pharmaceutical Co Ltd |
Cell injury inducing therapeutic drug for use in cancer therapy
|
RS64266B1
(sr)
|
2016-03-22 |
2023-07-31 |
Hoffmann La Roche |
Bispecifični molekul koji aktivira t ćeliju koji se aktivira proteazom
|
SI3443006T1
(sl)
|
2016-04-13 |
2024-01-31 |
Sanofi |
Trispecifični in/ali trivalentni vezni proteini
|
AR108295A1
(es)
|
2016-04-20 |
2018-08-08 |
Regeneron Pharma |
Composiciones y métodos para preparar anticuerpos basados en el uso de un locus mejorador de expresión
|
AR109451A1
(es)
|
2016-04-20 |
2018-12-12 |
Regeneron Pharma |
Composiciones y métodos para preparar anticuerpos basados en el uso de loci mejoradores de expresión
|
TWI786044B
(zh)
|
2016-05-13 |
2022-12-11 |
美商再生元醫藥公司 |
藉由投予pd-1抑制劑治療皮膚癌之方法
|
JP7101621B2
(ja)
|
2016-05-20 |
2022-07-15 |
ハープーン セラピューティクス,インク. |
単一ドメイン血清アルブミン結合タンパク質
|
US11623958B2
(en)
|
2016-05-20 |
2023-04-11 |
Harpoon Therapeutics, Inc. |
Single chain variable fragment CD3 binding proteins
|
EA201892693A1
(ru)
|
2016-05-20 |
2019-04-30 |
Харпун Терапьютикс, Инк. |
Белки, содержащие одноцепочечный вариабельный фрагмент, связывающийся с cd3
|
EP3464352B1
(en)
*
|
2016-05-27 |
2021-03-24 |
Altor BioScience Corporation |
Construction and characterization of multimeric il-15-based molecules with cd3 binding domains
|
EP3252078A1
(en)
|
2016-06-02 |
2017-12-06 |
F. Hoffmann-La Roche AG |
Type ii anti-cd20 antibody and anti-cd20/cd3 bispecific antibody for treatment of cancer
|
TW201902512A
(zh)
|
2016-06-02 |
2019-01-16 |
瑞士商赫孚孟拉羅股份公司 |
治療方法
|
KR20230054508A
(ko)
|
2016-06-14 |
2023-04-24 |
젠코어 인코포레이티드 |
이중특이적 체크포인트 억제제 항체
|
MX2018016364A
(es)
|
2016-06-20 |
2019-11-28 |
Kymab Ltd |
Anticuerpos anti-pd-l1.
|
CA3029209A1
(en)
|
2016-06-21 |
2017-12-28 |
Teneobio, Inc. |
Cd3 binding antibodies
|
US11525009B2
(en)
|
2016-06-22 |
2022-12-13 |
Benhealth Biopharmaceutic (Shenzhen) Co. Ltd. |
Bispecific antibody and antibody conjugate for tumor therapy and use thereof
|
CN116063545A
(zh)
|
2016-06-28 |
2023-05-05 |
Xencor股份有限公司 |
结合生长抑素受体2的异源二聚抗体
|
CN107573416A
(zh)
*
|
2016-06-30 |
2018-01-12 |
中国科学院深圳先进技术研究院 |
抗igf1r和cd3特异性双靶向抗体、含该双靶向抗体表达盒的微环dna及应用
|
CA3030427A1
(en)
|
2016-07-13 |
2018-01-18 |
President And Fellows Of Harvard College |
Antigen-presenting cell-mimetic scaffolds and methods for making and using the same
|
CN107759694B
(zh)
*
|
2016-08-19 |
2023-01-13 |
安源医药科技(上海)有限公司 |
双特异性抗体及其制备方法与用途
|
WO2018039499A1
(en)
|
2016-08-24 |
2018-03-01 |
Regeneron Pharmaceuticals, Inc. |
Host cell protein modification
|
US10793632B2
(en)
|
2016-08-30 |
2020-10-06 |
Xencor, Inc. |
Bispecific immunomodulatory antibodies that bind costimulatory and checkpoint receptors
|
CN109843325B
(zh)
|
2016-09-14 |
2023-10-03 |
特尼奥生物股份有限公司 |
Cd3结合抗体
|
AU2017331361B2
(en)
|
2016-09-23 |
2024-07-18 |
Regeneron Pharmaceuticals, Inc. |
Anti-STEAP2 antibodies, antibody-drug conjugates, and bispecific antigen-binding molecules that bind STEAP2 and CD3, and uses thereof
|
RS63660B1
(sr)
|
2016-09-23 |
2022-11-30 |
Regeneron Pharma |
Anti-muc16 (mucin 16) antitela
|
AU2017337073A1
(en)
*
|
2016-09-30 |
2019-04-18 |
Baylor College Of Medicine |
Antibody based gene therapy with tissue-directed expression
|
CN109843926B
(zh)
|
2016-09-30 |
2023-01-20 |
豪夫迈·罗氏有限公司 |
针对cd3的双特异性抗体
|
JP7273453B2
(ja)
|
2016-10-14 |
2023-05-15 |
ゼンコア インコーポレイテッド |
IL-15/IL-15RアルファFc融合タンパク質およびPD-1抗体の断片を含む二重特異性ヘテロ二量体融合タンパク質
|
WO2018093821A1
(en)
*
|
2016-11-15 |
2018-05-24 |
Genentech, Inc. |
Dosing for treatment with anti-cd20/anti-cd3 bispecific antibodies
|
JP6812551B2
(ja)
|
2016-11-23 |
2021-01-13 |
ハープーン セラピューティクス,インク. |
前立腺特異的膜抗原結合タンパク質
|
CA3044729A1
(en)
|
2016-11-23 |
2018-05-31 |
Harpoon Therapeutics, Inc. |
Psma targeting trispecific proteins and methods of use
|
CA3045296A1
(en)
|
2016-12-07 |
2018-06-14 |
Progenity, Inc. |
Gastrointestinal tract detection methods, devices and systems
|
MA46814B2
(fr)
|
2017-02-10 |
2022-09-30 |
Regeneron Pharma |
Anticorps anti-lag3 radiomarqués pour imagerie immuno-pet
|
CA3054289A1
(en)
|
2017-02-21 |
2018-08-30 |
Regeneron Pharmaceuticals, Inc. |
Anti-pd-1 antibodies for treatment of lung cancer
|
MX2019009967A
(es)
|
2017-02-24 |
2019-12-02 |
Macrogenics Inc |
Moleculas de union biespecificas que son capaces de unirse a cd137 y a antigenos tumorales, y usos de las mismas.
|
WO2018160754A2
(en)
|
2017-02-28 |
2018-09-07 |
Harpoon Therapeutics, Inc. |
Inducible monovalent antigen binding protein
|
PT3443006T
(pt)
*
|
2017-03-17 |
2023-10-26 |
Sanofi Sa |
Proteínas de ligação triespecíficas e/ou trivalentes
|
EP3604340A4
(en)
*
|
2017-03-24 |
2021-01-06 |
Zenyaku Kogyo Co., Ltd |
ANTI-IGM / B-CELL SURFACE ANTIGEN-BISPECIFIC ANTIBODY
|
EP4108183A1
(en)
|
2017-03-30 |
2022-12-28 |
Biora Therapeutics, Inc. |
Treatment of a disease of the gastrointestinal tract with an immune modulatory agent released using an ingestible device
|
US11603407B2
(en)
|
2017-04-06 |
2023-03-14 |
Regeneron Pharmaceuticals, Inc. |
Stable antibody formulation
|
KR20200026810A
(ko)
|
2017-05-12 |
2020-03-11 |
하푼 테라퓨틱스, 인크. |
Msln 표적화 삼중 특이적 단백질 및 사용 방법
|
IL300964A
(en)
|
2017-05-12 |
2023-04-01 |
Harpoon Therapeutics Inc |
mesothelin binding proteins
|
EP3409322A1
(en)
|
2017-06-01 |
2018-12-05 |
F. Hoffmann-La Roche AG |
Treatment method
|
WO2018237037A2
(en)
|
2017-06-20 |
2018-12-27 |
Teneobio, Inc. |
HEAVY CHAIN ANTIBODY ONLY ANTI-BCMA
|
CA3065951A1
(en)
|
2017-06-20 |
2018-12-27 |
Teneoone, Inc. |
Anti-bcma heavy chain-only antibodies
|
JP2020529832A
(ja)
|
2017-06-30 |
2020-10-15 |
ゼンコア インコーポレイテッド |
IL−15/IL−15Rαおよび抗原結合ドメインを含む標的化ヘテロダイマーFc融合タンパク質
|
CN114075269A
(zh)
|
2017-07-06 |
2022-02-22 |
菲仕兰坎皮纳荷兰私人有限公司 |
用于制备糖蛋白的细胞培养工艺
|
WO2019045856A1
(en)
*
|
2017-08-28 |
2019-03-07 |
Systimmune, Inc. |
ANTI-CD ANTIBODIES AND METHODS OF MAKING AND USING THEM
|
WO2019060823A1
(en)
*
|
2017-09-22 |
2019-03-28 |
The Regents Of The University Of California |
INTERFÉRON-GAMMA MITIGATES ANTITUMOR IMMUNE RESPONSE TO A BLOCKING OF CONTROL POINTS
|
MX2020002976A
(es)
*
|
2017-09-29 |
2020-07-24 |
Regeneron Pharma |
Moleculas de union a antigeno biespecificas que se unen a un antigeno objetivo de staphylococcus y a un componente de complemento, y usos de las mismas.
|
EA202090739A1
(ru)
|
2017-10-13 |
2020-09-07 |
Харпун Терапьютикс, Инк. |
Белки, связывающие антиген созревания в-клеток
|
PE20201183A1
(es)
|
2017-10-13 |
2020-11-03 |
Harpoon Therapeutics Inc |
Proteinas trispecificas y metodos de uso
|
EP3694885A1
(en)
|
2017-10-14 |
2020-08-19 |
CytomX Therapeutics, Inc. |
Antibodies, activatable antibodies, bispecific antibodies, and bispecific activatable antibodies and methods of use thereof
|
KR101973060B1
(ko)
|
2017-10-20 |
2019-04-26 |
주식회사 녹십자 |
항-cd3 항체 및 이를 포함하는 암 치료용 약학적 조성물
|
US10981992B2
(en)
|
2017-11-08 |
2021-04-20 |
Xencor, Inc. |
Bispecific immunomodulatory antibodies that bind costimulatory and checkpoint receptors
|
KR20200085828A
(ko)
|
2017-11-08 |
2020-07-15 |
젠코어 인코포레이티드 |
신규의 항-pd-1 서열을 사용한 이중특이적 및 단일특이적 항체
|
US11319355B2
(en)
|
2017-12-19 |
2022-05-03 |
Xencor, Inc. |
Engineered IL-2 Fc fusion proteins
|
AU2018392088A1
(en)
|
2017-12-22 |
2020-08-13 |
Teneobio, Inc. |
Heavy chain antibodies binding to CD22
|
MX2020006639A
(es)
|
2017-12-22 |
2020-09-14 |
Regeneron Pharma |
Sistema y metodo para caracterizar las impurezas de un producto farmaceutico.
|
WO2019152303A1
(en)
|
2018-01-31 |
2019-08-08 |
Regeneron Pharmaceuticals, Inc. |
Systems and methods for characterizing drug product impurities
|
TWI786265B
(zh)
|
2018-02-02 |
2022-12-11 |
美商再生元醫藥公司 |
用於表徵蛋白質二聚合之系統及方法
|
AR115360A1
(es)
|
2018-02-08 |
2021-01-13 |
Genentech Inc |
Moléculas de unión al antígeno y métodos de uso
|
BR112020015052A2
(pt)
|
2018-02-09 |
2020-12-08 |
Genmab A/S |
Composição farmacêutica, uso da composição farmacêutica, métodos para tratar câncer em um sujeito, para preparar uma composição farmacêutica e para preparar uma forma de dosagem unitária, forma de dosagem unitária, recipiente, e, kit-de-partes
|
BR112020013426A2
(pt)
|
2018-02-28 |
2020-12-01 |
Regeneron Pharmaceuticals, Inc. |
métodos para identificação de um vírus em uma amostra e para detecção de ácidos nucleicos virais em uma amostra de cultura de células
|
TWI779177B
(zh)
|
2018-03-19 |
2022-10-01 |
美商再生元醫藥公司 |
微晶片毛細管電泳分析及試劑
|
US10982006B2
(en)
|
2018-04-04 |
2021-04-20 |
Xencor, Inc. |
Heterodimeric antibodies that bind fibroblast activation protein
|
EP3781599A1
(en)
|
2018-04-18 |
2021-02-24 |
Xencor, Inc. |
Pd-1 targeted heterodimeric fusion proteins containing il-15/il-15ra fc-fusion proteins and pd-1 antigen binding domains and uses thereof
|
JP2021520829A
(ja)
|
2018-04-18 |
2021-08-26 |
ゼンコア インコーポレイテッド |
IL−15/IL−15RA Fc融合タンパク質およびTIM−3抗原結合ドメインを含む、TIM−3標的化ヘテロ二量体融合タンパク質
|
TW202016125A
(zh)
|
2018-05-10 |
2020-05-01 |
美商再生元醫藥公司 |
用於定量及調節蛋白質黏度之系統與方法
|
CR20200568A
(es)
*
|
2018-05-24 |
2021-02-26 |
Janssen Biotech Inc |
Antcuerpos anti-cd3 y usos de estos
|
CN110540593B
(zh)
*
|
2018-05-29 |
2022-05-17 |
上海药明生物技术有限公司 |
新型的抗cd3/抗cd20双特异性抗体
|
WO2019246312A1
(en)
|
2018-06-20 |
2019-12-26 |
Progenity, Inc. |
Treatment of a disease of the gastrointestinal tract with an immunomodulator
|
WO2019246317A1
(en)
|
2018-06-20 |
2019-12-26 |
Progenity, Inc. |
Treatment of a disease or condition in a tissue originating from the endoderm
|
MX2020013804A
(es)
|
2018-06-21 |
2021-03-31 |
Regeneron Pharma |
Anticuerpos anti-psma x anti-cd28 biespecíficos y usos de estos.
|
TWI838389B
(zh)
|
2018-07-19 |
2024-04-11 |
美商再生元醫藥公司 |
雙特異性抗-BCMAx抗-CD3抗體及其用途
|
KR20210049863A
(ko)
|
2018-08-23 |
2021-05-06 |
리제너론 파아마슈티컬스, 인크. |
항-Fc 엡실론-R1 알파 (FCERIA) 항체, FCERIA 및 CD3에 결합하는 이중특이적 항원-결합 분자 및 이들의 용도
|
MX2021002279A
(es)
|
2018-08-27 |
2021-05-27 |
Regeneron Pharma |
Uso de espectroscopia raman en la purificacion corriente abajo.
|
US11754569B2
(en)
|
2018-08-30 |
2023-09-12 |
Regeneron Pharmaceuticals, Inc. |
Methods for characterizing protein complexes
|
WO2020047389A1
(en)
|
2018-08-31 |
2020-03-05 |
Regeneron Pharmaceuticals, Inc. |
Dosing strategy that mitigates cytokine release syndrome for cd3/c20 bispecific antibodies
|
BR112021005769A2
(pt)
|
2018-09-25 |
2021-07-06 |
Harpoon Therapeutics Inc |
proteínas de ligação a dll3 e métodos de uso
|
US11358999B2
(en)
|
2018-10-03 |
2022-06-14 |
Xencor, Inc. |
IL-12 heterodimeric Fc-fusion proteins
|
SG11202103628PA
(en)
|
2018-10-31 |
2021-05-28 |
Regeneron Pharma |
Method and system of identifying and quantifying a protein
|
US20220249814A1
(en)
|
2018-11-19 |
2022-08-11 |
Progenity, Inc. |
Methods and devices for treating a disease with biotherapeutics
|
US11249089B2
(en)
|
2018-12-12 |
2022-02-15 |
Regeneron Pharmaceuticals, Inc. |
System and method of analysis of a protein using liquid chromatography-mass spectrometry
|
AU2019405736A1
(en)
|
2018-12-19 |
2021-06-24 |
Regeneron Pharmaceuticals, Inc. |
Bispecific anti-MUC16 x anti-CD28 antibodies and uses thereof
|
WO2020132066A1
(en)
|
2018-12-19 |
2020-06-25 |
Regeneron Pharmaceuticals, Inc. |
Bispecific anti-cd28 x anti-cd22 antibodies and uses thereof
|
SG11202104103XA
(en)
|
2019-01-16 |
2021-05-28 |
Regeneron Pharma |
Methods for characterizing disulfide bonds
|
US20220169728A1
(en)
*
|
2019-01-28 |
2022-06-02 |
Ab Therapeutics, Inc. |
Bispecific antibodies and uses thereof
|
US20220106398A1
(en)
*
|
2019-02-08 |
2022-04-07 |
Igm Biosciences, Inc. |
Anti-gitr antigen-binding domains and uses thereof
|
CA3127696A1
(en)
|
2019-02-12 |
2020-08-20 |
Regeneron Pharmaceuticals, Inc. |
Compositions and methods for using bispecific antibodies to bind complement and a target antigen
|
US20220204603A1
(en)
*
|
2019-02-25 |
2022-06-30 |
Pharmabcine Inc. |
Anti-ang2 antibody and use thereof
|
WO2020180726A1
(en)
|
2019-03-01 |
2020-09-10 |
Xencor, Inc. |
Heterodimeric antibodies that bind enpp3 and cd3
|
TW202101000A
(zh)
*
|
2019-03-08 |
2021-01-01 |
美商建南德克公司 |
用於偵測且量化膜相關蛋白之方法
|
MX2021011500A
(es)
|
2019-03-22 |
2021-10-22 |
Regeneron Pharma |
Anticuerpos multiespecificos egfr x cd28.
|
TW202039578A
(zh)
|
2019-03-29 |
2020-11-01 |
荷蘭商美勒斯公司 |
Cd3結合分子
|
EP3946452A1
(en)
*
|
2019-04-04 |
2022-02-09 |
Janssen Biotech, Inc. |
Anti-hla-c antibodies and uses thereof
|
US11613576B2
(en)
|
2019-04-09 |
2023-03-28 |
Sanofi |
Trispecific binding proteins, methods, and uses thereof
|
JP7541534B2
(ja)
|
2019-05-13 |
2024-08-28 |
リジェネロン・ファーマシューティカルズ・インコーポレイテッド |
改善された競合的リガンド結合アッセイ
|
JP7137696B2
(ja)
|
2019-05-14 |
2022-09-14 |
プロヴェンション・バイオ・インコーポレイテッド |
1型糖尿病を予防するための方法および組成物
|
BR112021020426A2
(pt)
*
|
2019-06-07 |
2022-03-08 |
Adimab Llc |
Anticorpos anti-cd3 dependentes de ph projetados e métodos para sua geração e uso
|
UY38748A
(es)
|
2019-06-14 |
2021-01-29 |
Teneobio Inc |
Anticuerpos multiespecíficos de cadena pesada que se unen a cd22 y cd3
|
CN116987197A
(zh)
*
|
2019-06-20 |
2023-11-03 |
成都恩沐生物科技有限公司 |
共价多特异性抗体
|
US20200399372A1
(en)
|
2019-06-21 |
2020-12-24 |
Regeneron Pharmaceuticals, Inc. |
Use of bispecific antigen-binding molecules that bind psma and cd3 in combination with 4-1bb co-stimulation
|
DE102019121007A1
(de)
|
2019-08-02 |
2021-02-04 |
Immatics Biotechnologies Gmbh |
Antigenbindende Proteine, die spezifisch an MAGE-A binden
|
JP2022545647A
(ja)
*
|
2019-08-15 |
2022-10-28 |
リジェネロン・ファーマシューティカルズ・インコーポレイテッド |
細胞標的化のための多重特異性抗原結合分子およびそれらの使用
|
AU2020328195A1
(en)
|
2019-08-15 |
2022-03-03 |
Genmab A/S |
Pharmaceutical compositions comprising bispecific antibodies directed against CD3 and CD20 and their uses
|
CN112390882A
(zh)
*
|
2019-08-19 |
2021-02-23 |
杨洋 |
靶向cd3和cd20的双特异性抗体及其应用
|
RU2738802C1
(ru)
*
|
2019-08-21 |
2020-12-17 |
Общество с ограниченной ответственностью "Международный Биотехнологический Центр "Генериум" |
Определяющие комплементарность участки для связывания cd3 и содержащая их биспецифическая антигенсвязывающая молекула
|
AU2020352547A1
(en)
|
2019-09-24 |
2022-03-31 |
Regeneron Pharmaceuticals, Inc. |
Systems and methods for chromatography use and regeneration
|
JP2023502500A
(ja)
|
2019-11-25 |
2023-01-24 |
リジェネロン・ファーマシューティカルズ・インコーポレイテッド |
非水性エマルションを使用した持続放出製剤
|
BR112021025432A2
(pt)
|
2019-12-06 |
2022-06-21 |
Regeneron Pharma |
Composições de proteína anti-vegf e métodos para a produção das mesmas
|
AU2020398167A1
(en)
|
2019-12-06 |
2022-07-28 |
Regeneron Pharmaceuticals, Inc. |
Methods of treating multiple myeloma with bispecific anti-BCMA x anti-CD3 antibodies
|
TW202135860A
(zh)
|
2019-12-10 |
2021-10-01 |
美商再生元醫藥公司 |
含有抗cd20x抗cd3雙特異性抗體之穩定調配物
|
GB201918230D0
(en)
|
2019-12-11 |
2020-01-22 |
Prec Therapeutics Ltd |
Antibodies and their uses
|
PE20221511A1
(es)
|
2019-12-13 |
2022-10-04 |
Genentech Inc |
Anticuerpos anti-ly6g6d y metodos de uso
|
CN115666704A
(zh)
|
2019-12-13 |
2023-01-31 |
比奥拉治疗股份有限公司 |
用于将治疗剂递送至胃肠道的可摄取装置
|
MX2022008973A
(es)
|
2020-01-21 |
2022-08-11 |
Regeneron Pharma |
Metodos de desglicosilacion para electroforesis de proteinas glicosiladas.
|
KR20210095781A
(ko)
|
2020-01-24 |
2021-08-03 |
주식회사 에이프릴바이오 |
항원결합 단편 및 생리활성 이펙터 모이어티로 구성된 융합 컨스트럭트를 포함하는 다중결합항체 및 이를 포함하는 약학조성물
|
IL295448A
(en)
|
2020-02-21 |
2022-10-01 |
Harpoon Therapeutics Inc |
flt3 binding proteins and methods of use
|
CN113563473A
(zh)
|
2020-04-29 |
2021-10-29 |
三生国健药业(上海)股份有限公司 |
四价双特异性抗体、其制备方法和用途
|
US20230203161A1
(en)
|
2020-04-29 |
2023-06-29 |
Teneobio, Inc |
Multispecific heavy chain antibodies with modified heavy chain constant regions
|
EP4143573A1
(en)
|
2020-05-01 |
2023-03-08 |
Regeneron Pharmaceuticals, Inc. |
Neutralizing antibody assay for therapeutic proteins
|
KR20230008775A
(ko)
|
2020-05-08 |
2023-01-16 |
젠맵 에이/에스 |
Cd3 및 cd20에 대한 이중특이적 항체
|
US11919956B2
(en)
|
2020-05-14 |
2024-03-05 |
Xencor, Inc. |
Heterodimeric antibodies that bind prostate specific membrane antigen (PSMA) and CD3
|
AU2021287998A1
(en)
|
2020-06-11 |
2023-02-02 |
Benaroya Research Institute At Virginia Mason |
Methods and compositions for preventing type 1 diabetes
|
US11780920B2
(en)
|
2020-06-19 |
2023-10-10 |
Hoffmann-La Roche Inc. |
Antibodies binding to CD3 and CD19
|
KR20230166150A
(ko)
|
2020-08-19 |
2023-12-06 |
젠코어 인코포레이티드 |
항-cd28 조성물
|
CN112062855B
(zh)
*
|
2020-08-26 |
2024-08-30 |
北京天诺健成医药科技有限公司 |
一种含有衔接器的药物治疗剂的开发和应用
|
BR112023003273A2
(pt)
|
2020-08-31 |
2023-05-02 |
Regeneron Pharma |
Estratégias de alimentação de asparagina para melhorar desempenho da cultura celular e mitigar variantes da sequência de asparagina
|
US20230357440A1
(en)
|
2020-09-10 |
2023-11-09 |
Genmab A/S |
Bispecific antibody against cd3 and cd20 in combination therapy for treating follicular lymphoma
|
EP4210746A1
(en)
|
2020-09-10 |
2023-07-19 |
Genmab A/S |
Bispecific antibodies against cd3 and cd20 for treating chronic lymphocytic leukemia
|
IL301085A
(en)
|
2020-09-10 |
2023-05-01 |
Genmab As |
A bispecific antibody against CD3 and CD20 in combination therapy for the treatment of diffuse large B-cell lymphoma
|
EP4210742A1
(en)
|
2020-09-10 |
2023-07-19 |
Genmab A/S |
Bispecific antibody against cd3 and cd20 in combination therapy for treating follicular lymphoma
|
BR112023004296A2
(pt)
|
2020-09-10 |
2023-04-04 |
Genmab As |
Método para tratar linfoma de célula b grande difusa em um indivíduo humano
|
TW202227494A
(zh)
*
|
2020-09-11 |
2022-07-16 |
美商健生生物科技公司 |
多特異性免疫靶向分子及其用途
|
US11905332B2
(en)
|
2020-09-18 |
2024-02-20 |
Regeneron Pharmaceuticals, Inc. |
Antigen-binding molecules that bind CD38 and/or CD28, and uses thereof
|
JP2023544164A
(ja)
|
2020-10-02 |
2023-10-20 |
リジェネロン・ファーマシューティカルズ・インコーポレイテッド |
サイトカイン放出症候群の低減を伴うがんを治療するための抗体の組合せ
|
CA3191141A1
(en)
|
2020-11-25 |
2022-06-02 |
Hunter Chen |
Sustained release formulations using non-aqueous membrane emulsification
|
AU2021401301A1
(en)
|
2020-12-17 |
2023-08-03 |
Regeneron Pharmaceuticals, Inc. |
Fabrication of protein-encapsulating microgels
|
CA3202197A1
(en)
|
2021-01-20 |
2022-07-28 |
Reginald Smith |
Methods of improving protein titer in cell culture
|
CN116963774A
(zh)
|
2021-01-28 |
2023-10-27 |
瑞泽恩制药公司 |
用于治疗细胞因子释放综合征的组合物和方法
|
TW202246325A
(zh)
|
2021-03-03 |
2022-12-01 |
美商再生元醫藥公司 |
用於定量及修飾蛋白質黏度之系統及方法
|
KR20230156079A
(ko)
|
2021-03-09 |
2023-11-13 |
젠코어 인코포레이티드 |
Cd3과 cldn6에 결합하는 이종이량체 항체
|
WO2022192586A1
(en)
|
2021-03-10 |
2022-09-15 |
Xencor, Inc. |
Heterodimeric antibodies that bind cd3 and gpc3
|
JP2024519407A
(ja)
|
2021-03-26 |
2024-05-13 |
リジェネロン・ファーマシューティカルズ・インコーポレイテッド |
混合プロトコルを作成するための方法およびシステム
|
MX2023012699A
(es)
|
2021-04-30 |
2023-11-21 |
Hoffmann La Roche |
Dosificacion para el tratamiento con anticuerpo biespecifico anti-cd20/anti-cd3.
|
CN117321078A
(zh)
|
2021-04-30 |
2023-12-29 |
豪夫迈·罗氏有限公司 |
针对用抗cd20/抗cd3双特异性抗体和抗cd79b抗体药物缀合物进行组合治疗的给药
|
EP4348234A1
(en)
|
2021-06-01 |
2024-04-10 |
Regeneron Pharmaceuticals, Inc. |
Micropchip capillary electrophoresis assays and reagents
|
WO2022266660A1
(en)
*
|
2021-06-17 |
2022-12-22 |
Amberstone Biosciences, Inc. |
Anti-cd3 constructs and uses thereof
|
WO2022263507A1
(en)
|
2021-06-17 |
2022-12-22 |
Boehringer Ingelheim International Gmbh |
Novel tri-specific binding molecules
|
WO2023028612A2
(en)
|
2021-08-27 |
2023-03-02 |
Board Of Regents, The University Of Texas System |
Anti-tslpr (crlf2) antibodies
|
TW202326138A
(zh)
|
2021-09-08 |
2023-07-01 |
美商再生元醫藥公司 |
用於定量抗體及其他含Fc蛋白之高通量及基於質譜之方法
|
IL311527A
(en)
|
2021-09-20 |
2024-05-01 |
Regeneron Pharma |
Methods for controlling antibody heterogeneity
|
EP4410840A1
(en)
*
|
2021-09-30 |
2024-08-07 |
Betta Pharmaceuticals Co., Ltd |
Bispecific antibody and application thereof
|
CN118076894A
(zh)
|
2021-10-07 |
2024-05-24 |
里珍纳龙药品有限公司 |
pH建模和控制的系统及方法
|
TW202331252A
(zh)
|
2021-10-07 |
2023-08-01 |
美商再生元醫藥公司 |
Ph計校準與校正
|
CN118176167A
(zh)
|
2021-10-26 |
2024-06-11 |
瑞泽恩制药公司 |
用于产生实验室用水和分配处于不同温度的实验室用水的系统和方法
|
IL312302A
(en)
|
2021-10-28 |
2024-06-01 |
Lyell Immunopharma Inc |
Methods for creating cells
|
WO2023133595A2
(en)
|
2022-01-10 |
2023-07-13 |
Sana Biotechnology, Inc. |
Methods of ex vivo dosing and administration of lipid particles or viral vectors and related systems and uses
|
WO2023138551A1
(zh)
*
|
2022-01-20 |
2023-07-27 |
上海君实生物医药科技股份有限公司 |
抗cd3和抗cd20双特异性抗体及其用途
|
WO2023150518A1
(en)
|
2022-02-01 |
2023-08-10 |
Sana Biotechnology, Inc. |
Cd3-targeted lentiviral vectors and uses thereof
|
TW202346856A
(zh)
|
2022-03-18 |
2023-12-01 |
美商里珍納龍藥品有限公司 |
分析多肽變體的方法及系統
|
CN118434772A
(zh)
*
|
2022-03-23 |
2024-08-02 |
上海济煜医药科技有限公司 |
一种抗cd3抗体、其制备方法及应用
|
AU2023238766A1
(en)
|
2022-03-23 |
2024-07-25 |
F. Hoffmann-La Roche Ag |
Combination treatment of an anti-cd20/anti-cd3 bispecific antibody and chemotherapy
|
WO2023192850A1
(en)
|
2022-03-29 |
2023-10-05 |
Ngm Biopharmaceuticals, Inc. |
Ilt3 and cd3 binding agents and methods of use thereof
|
WO2023193015A1
(en)
|
2022-04-01 |
2023-10-05 |
Sana Biotechnology, Inc. |
Cytokine receptor agonist and viral vector combination therapies
|
WO2023201226A1
(en)
|
2022-04-11 |
2023-10-19 |
Regeneron Pharmaceuticals, Inc. |
Compositions and methods for universal tumor cell killing
|
WO2023198839A2
(en)
|
2022-04-13 |
2023-10-19 |
Genmab A/S |
Bispecific antibodies against cd3 and cd20
|
TW202404637A
(zh)
|
2022-04-13 |
2024-02-01 |
瑞士商赫孚孟拉羅股份公司 |
抗cd20/抗cd3雙特異性抗體之醫藥組成物及使用方法
|
WO2023214960A1
(en)
|
2022-05-02 |
2023-11-09 |
Regeneron Pharmaceuticals, Inc. |
Biochemical assays for therapeutic proteins
|
US20230416396A1
(en)
|
2022-05-18 |
2023-12-28 |
Regeneron Pharmaceuticals, Inc. |
Multispecific antigen binding molecules that bind cd38 and 4-1bb, and uses thereof
|
WO2023235805A2
(en)
*
|
2022-06-01 |
2023-12-07 |
The Wistar Institute Of Anatomy And Biology |
Dna-encoded bispecific antibodies targeting carbonic anhydrase 9 and methods of use in cancer therapeutics
|
WO2024012513A1
(en)
*
|
2022-07-13 |
2024-01-18 |
Hansoh Bio Llc |
Antibody, antigen-binding fragment thereof, and pharmaceutical use thereof
|
WO2024030453A1
(en)
|
2022-08-02 |
2024-02-08 |
Regeneron Pharmaceuticals, Inc. |
Methods of treating metastatic castration-resistant prostate cancer with bispecific anti-psma x anti-cd28 antibodies in combination with anti-pd-1 antibodies
|
WO2024044655A1
(en)
|
2022-08-24 |
2024-02-29 |
Sana Biotechnology, Inc. |
Delivery of heterologous proteins
|
WO2024077174A1
(en)
|
2022-10-05 |
2024-04-11 |
Lyell Immunopharma, Inc. |
Methods for culturing nr4a-deficient cells
|
WO2024088987A1
(en)
|
2022-10-26 |
2024-05-02 |
F. Hoffmann-La Roche Ag |
Combination therapy for the treatment of cancer
|
CN116023499B
(zh)
*
|
2022-10-26 |
2024-01-23 |
北京力邦生物医药科技有限公司 |
一种针对cd3和cd20的双特异性抗体
|
WO2024119157A1
(en)
|
2022-12-02 |
2024-06-06 |
Sana Biotechnology, Inc. |
Lipid particles with cofusogens and methods of producing and using the same
|
WO2024123698A1
(en)
|
2022-12-08 |
2024-06-13 |
Regeneron Pharmaceuticals, Inc. |
Methods to characterizing a fragment crystallizable domain of a bispecific antibody
|
US20240198253A1
(en)
|
2022-12-16 |
2024-06-20 |
Regeneron Pharmaceuticals, Inc. |
Methods and systems for assessing chromatographic column integrity
|
US20240248097A1
(en)
|
2023-01-25 |
2024-07-25 |
Regeneron Pharmaceuticals, Inc. |
Mass spectrometry-based characterization of antibodies co-expressed in vivo
|
US20240245779A1
(en)
|
2023-01-25 |
2024-07-25 |
Regeneron Pharmaceuticals, Inc. |
Methods of modeling liquid protein composition stability
|
WO2024173830A2
(en)
|
2023-02-17 |
2024-08-22 |
Regeneron Pharmaceuticals, Inc. |
Induced nk cells responsive to cd3/taa bispecific antibodies
|
US20240280551A1
(en)
|
2023-02-22 |
2024-08-22 |
Regeneron Pharmaceuticals, Inc. |
System suitability parameters and column aging
|